David Engler - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

David Engler

Showing results (11-20 of 16) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 16 results.

Multiple Sclerosis International|April 5, 2013

Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosisBrian C Healy, David Engler, Bonnie Glanz, et al.

Journal of the Neurological Sciences|January 22, 2011

Accounting for disease modifying therapy in models of clinical progression in multiple sclerosisBrian C Healy, David Engler, Taha Gholipour, et al.

Multiple Sclerosis and Related Disorders|February 15, 2019

Time between expanded disability status scale (EDSS) scoresJonathan Zurawski, Bonnie I Glanz, Alicia Chua, et al.

Journal of Controlled Release : Official Journal of the Controlled Release Society|September 27, 2015

Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrierKenji Yokoi, Diana Chan, Milos Kojic, et al.

Journal of Neuropathology and Experimental Neurology|November 18, 2009

Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcomeDarlene Gabeau-Lacet, David Engler, Sumeet Gupta, et al.

Nucleic Acids Research|August 2, 2012

Deoxycytidine kinase regulates the G2/M checkpoint through interaction with cyclin-dependent kinase 1 in response to DNA damageChunying Yang, Michael Lee, Jianwei Hao, et al.

Pageof 2

Search research articles

Showing results (11-20 of 16) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 16 results.

Multiple Sclerosis International|April 5, 2013

Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosisBrian C Healy, David Engler, Bonnie Glanz, et al.

Journal of the Neurological Sciences|January 22, 2011

Accounting for disease modifying therapy in models of clinical progression in multiple sclerosisBrian C Healy, David Engler, Taha Gholipour, et al.

Multiple Sclerosis and Related Disorders|February 15, 2019

Time between expanded disability status scale (EDSS) scoresJonathan Zurawski, Bonnie I Glanz, Alicia Chua, et al.

Journal of Controlled Release : Official Journal of the Controlled Release Society|September 27, 2015

Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrierKenji Yokoi, Diana Chan, Milos Kojic, et al.

Journal of Neuropathology and Experimental Neurology|November 18, 2009

Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcomeDarlene Gabeau-Lacet, David Engler, Sumeet Gupta, et al.

Nucleic Acids Research|August 2, 2012

Deoxycytidine kinase regulates the G2/M checkpoint through interaction with cyclin-dependent kinase 1 in response to DNA damageChunying Yang, Michael Lee, Jianwei Hao, et al.

Pageof 2